Abstract |
This study investigated the efficacy and tolerability of ZD9331 as second- or third-line treatment for patients with advanced colorectal cancer (aCRC). One hundred patients were recruited to the study: 45 in group 1 (failed first-line 5-FU-based regimen) and 55 in group 2 (failed first-line 5-FU-based regimen and second-line irinotecan). Patients received ZD9331 as a 30-minute intravenous infusion on days 1 and 8 of a 3-week cycle, and treatment continued until disease progression (PD) or withdrawal. After a median of 4 cycles of treatment, there were no objective responses in group 1 (N = 37), 25 (67.6%) patients had a best overall response of stable disease (SD), and 12 (32.4%) had PD. After a median of 3 cycles of treatment, there were 2 (4.5%) partial responses in group 2 (N = 44), 21 (47.7%) patients had a best overall response of SD, 20 (45.4%) had PD, and 1 (2.3%) had clinical progression. At data cut-off, 59.5% and 77.3% of patients in groups 1 and 2, respectively, had PD. The main adverse events were neutropenia (69%), fatigue (53%), nausea (46%), and diarrhea (40%), and most (72.3%) were grade I/II. ZD9331 demonstrated minimal antitumor activity, and manageable toxicity, in the second- or third-line treatment of aCRC.
|
Authors | J Schulz, A Keller, V Canfield, G Parker, E Douglass |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 27
Issue 4
Pg. 337-42
(Aug 2004)
ISSN: 1537-453X [Electronic] United States |
PMID | 15289725
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Quinazolines
- ZD 9331
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Colorectal Neoplasms
(drug therapy, pathology)
- Drug Resistance, Neoplasm
- Female
- Humans
- Male
- Middle Aged
- Quinazolines
(therapeutic use)
|